• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A safe, effective diet pill - the elusive holy grail
Trade in illegal, ineffective drugs flourishes as pharmaceutical industry repeatedly fails to produce successful pillAttempts to invent a safe and effective diet pill have foundered time and again, allowing the internet trade in illegal and ineffective herbal supplements and dangerous drugs, such as DNP, to flourish.A successful diet pill could make billions for the pharmaceutical industry, but efforts to date have ended in disaster, with patients harmed, drugs banned and massive compensation paid out.Fen-phen, an appetite suppressant, was the most spectacular failure. It was withdrawn in the US in 1997 after causing wides...
Source: Guardian Unlimited Science - January 14, 2014 Category: Science Authors: Sarah Boseley Tags: The Guardian Diets and dieting Drugs trade Healthcare industry World news Pharmaceuticals industry & wellbeing Health policy Society Politics UK news Life and style Public services policy Business Science Source Type: news

Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate.
Abstract Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common of the pediatric neuropsychiatric disorders. Methylphenidate is an important element of therapeutic strategies for ADHD. Clinicians are interested in the safety of methylphenidate. Because this drug raises heart rate and blood pressure, concerns have been raised about its cardiovascular safety. Concerns were based on case reports of sudden cardiac death in methylphenidate users, plausible pharmacological pathways involving well-established stimulant effects on heart rate and blood pressure. Until recently, data were limited to a num...
Source: Archives de Pediatrie - December 2, 2013 Category: Pediatrics Authors: Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC Tags: Arch Pediatr Source Type: research

Author reply
Beaumont et al and Ueta raise concerns about the systemic safety of aflibercept for intravitreal injection, particularly regarding cerebrovascular risk and stroke, based on their analysis of safety data from the VIEW studies comparing aflibercept to ranibizumab. They acknowledge similar rates of serious adverse events (SAEs) overall between aflibercept and ranibizumab, as well as similar rates of myocardial infarction, stroke, and vascular death as confirmed by masked adjudication using the strict and well-accepted Antiplatelet Trialists' Collaboration (APTC) criteria. However, they focus on numerical imbalances in certai...
Source: Ophthalmology - November 19, 2013 Category: Opthalmology Authors: Jeffrey S. Heier, David M. Brown, Victor Chong, Jean-Francois Korobelnik, Peter K. Kaiser, Quan Dong Nguyen, Bernd Kirchhof, Allen Ho, Yuichiro Ogura, Ursula Schmidt-Erfurth Tags: Correspondence Source Type: research

Families face battle with GSK over dangerous diabetes drug
Exclusive: Pharmaceutical giant resists claims despite settlement with victims in USThousands of families in the UK could be deprived of compensation for the death or harm of a relative caused by the diabetes drug Avandia, even though the British maker has agreed to pay billions of dollars to settle similar claims in the US.The licence for Avandia was revoked in Europe, in September 2010, because of evidence that it could cause heart failure and heart attacks. The drug can still be prescribed in the US, but not to patients at risk of heart problems.A scientist with the Food and Drug Administration estimated that Avandia co...
Source: Guardian Unlimited Science - January 29, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian United States World news Pharmaceuticals industry Medical research Legal aid Law UK news Diabetes GlaxoSmithKline Business Source Type: news

Pages: 1  2